The FDA urges manufacturers to revise labeling of transmucosal buprenorphine products to ease access to higher doses because ...
HHS and the Drug Enforcement Administration have finalized a rule that expands telemedicine prescribing of buprenorphine for opioid use disorder, while also proposing a new special registration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback